FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
Open Access
- 21 February 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (12) , 2488-2492
Abstract
On July 16, 2021, the FDA approved belumosudil, a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic GvHD (cGvHD) after failure of at least two prior lines of systemic therapy. Approval was based on the results of Study KD025–213, which included 65 patients with cGvHD treated with belumosudil 200 mg daily in an open-label, single-arm cohort. Efficacy was determined by the overall response rate (ORR) through Cycle 7 Day 1, which included complete response (CR) or partial response (PR) according to the 2014 NIH consensus criteria, and durability of response. The ORR through Cycle 7 Day 1 was 75% [95% confidence interval (CI), 63–85]; 6% of patients achieved a CR, and 69% achieved a PR. The median duration of response was 1.9 months (95% CI, 1.2–2.9), and 62% (95% CI, 46–74) of responding patients remained alive without new systemic therapy for at least 12 months from response. The common adverse reactions were infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma-glutamyl transferase increased, lymphocytes decreased, and hypertension. Additional study is warranted to confirm safety with long-term use.Keywords
All Related Versions
Funding Information
- HHS | U.S. Food and Drug Administration
This publication has 14 references indexed in Scilit:
- ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host DiseaseJournal of Clinical Oncology, 2021
- PTH/PTHrP Receptor Signaling Restricts Arterial Fibrosis in Diabetic LDLR −/− Mice by Inhibiting Myocardin-Related Transcription Factor RelaysCirculation Research, 2020
- Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2018
- The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2017
- Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanismBlood, 2016
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2015
- Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanismProceedings of the National Academy of Sciences, 2014
- Rho-associated coiled-coil containing kinases (ROCK)Small GTPases, 2014
- Rho-kinase: regulation, (dys)function, and inhibitionBiological Chemistry, 2013
- Chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2003